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Abstract
Background: Drug resistance testing before initiation of, or during, antiretroviral therapy (ART) is not routinely
performed in resource-limited settings. High levels of viral resistance circulating within the population will have
impact on treatment programs by increasing the chances of transmission of resistant strains and treatment failure.
Here, we investigate Drug Resistance Mutations (DRMs) from blood samples obtained at regular intervals from
patients on ART (Baseline-22 months) in Karonga District, Malawi. One hundred and forty nine reverse transcriptase
(RT) consensus sequences were obtained via nested PCR and automated sequencing from blood samples collected
at three-month intervals from 75 HIV-1 subtype C infected individuals in the ART programme.
Results: Fifteen individuals showed DRMs, and in ten individuals DRMs were seen from baseline samples (reported
to be ART naïve). Three individuals in whom no DRMs were observed at baseline showed the emergence of DRMs
during ART exposure. Four individuals who did show DRMs at baseline showed additional DRMs at subsequent
time points, while two individuals showed evidence of DRMs at baseline and either no DRMs, or different DRMs, at
later timepoints. Three individuals had immune failure but none appeared to be failing clinically.
Conclusion: Despite the presence of DRMs to drugs included in the current regimen in some individuals, and
immune failure in three, no signs of clinical failure were seen during this study. This cohort will continue to be
monitored as part of the Karonga Prevention Study so that the long-term impact of these mutations can be
assessed. Documenting proviral population is also important in monitoring the emergence of drug resistance as
selective pressure provided by ART compromises the current plasma population, archived viruses can re-emerge
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Introduction
It has been estimated that in sub-Saharan Africa, approxi-
mately 3.9 million people have started antiretroviral treat-
ment (ART) since its introduction (UNAIDS, 2010). Given
the large population on treatment, viral diversity coupled
with low adherence could lead to the emergence and
large-scale transmission of drug resistant strains. Rates of
drug resistance among patients who received ART in sub-
Saharan Africa range from 3.7%-49% after 24-163 weeks
of HAART [1]. Various factors contribute to this large
range in resistance among African cohorts such as varia-
tion in available healthcare systems and practices, adher-
ence, and access to monitoring [2]. Development of DRMs
to Trioimmune®, the drug combination used as first line
therapy in Karonga District, Malawi, has been reported in
Zambia [3], South Africa [4], Cameroon [5], Kenya [6] and
Uganda [7]. Previous studies on drug resistance in Malawi
showed various DRMs to both NRTIs and NNRTIs in
both drug naïve individuals [8] and those failing therapy
[9]. However, very little data is yet available on the emer-
gence of drug resistance to ongoing treatment and the
transmission of drug resistant variants in subtype C
infected countries [3,5-7,10].* Correspondence: grace.mccormack@nuigalway.ie1Molecular Evolution and Systematics Laboratory, Zoology, Ryan Institute,
School of Natural Sciences, National University of Ireland, Galway, Ireland
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The Malawi antiretroviral treatment (ART) program
started in 2004, and between then and the end of June
2010 over 225, 000 patients had initiated first-line antire-
troviral therapy (ART) through 396 ART clinics [11]. As
part of the Karonga Prevention Study (KPS), investigating
how the availability and use of ART may change the HIV
epidemic and its socio-demographic impact in the rural
Karonga District, (northern Malawi), an ART research
cohort was established from those attending the ART
clinic at Chilumba Rural Hospital. HIV-1 subtype C is
the predominant subtype in this District [12]. The objec-
tive of this overall study was to investigate the success of
the current ART delivery programme in a rural popula-
tion, and, as a component of this, to investigate the evo-
lution of drug resistance using a traditional consensus
sequence genotyping approach.
Materials and methods
Study Participants and Treatment schedules
At the Ministry of Health ART clinic at Chilumba Rural
Hospital all those attending for screening for ART suit-
ability and who are resident in a geographically defined
area adjacent to the clinic, are invited to take part in an
observational cohort study. Every three months partici-
pants are clinically assessed by KPS research staff. Blood
samples are collected at the their first visit (baseline) and
at every follow-up visit. A CD4 count is performed at
baseline, 6, 12 and 24 months or at the time of a clinical
failure, defined by a new WHO stage 3 or 4 event after
six months of therapy (WHO, 2006). First line therapy is
a generic fixed-dose combination treatment (Triom-
mune®), which consists of: stavudine (d4T), lamivudine
(3TC), and nevirapine (NVP). All individuals were on
first line therapy only.
DNA Extraction, PCR and Sequencing
Whole blood samples were collected in 4.5 ml vacutainer
tubes. Samples were centrifuged and plasma and cell pel-
let were stored separately at -70°C. DNA was extracted
from whole blood cell pellet samples using the QIAamp
DNA Blood Mini Kit (QIAGEN ltd). Extracted DNA was
subjected to nested PCR amplification of the HIV-1
reverse transcriptase as described in Bansode et al [13].
All PCR amplicons were gel purified and automatically
sequenced.
Sequence Analyses
Sequence chromatographs were edited in SeqMan
(DNASTAR, Inc) and all sites that showed ambiguities
(two or more peaks of equal, or almost equal, height) were
noted. Multiple alignments were assembled of all subtype
C sequences generated with the 57 reverse transcriptase
sequences generated from [13] using MacClade 4.0
(Sinauer Assoc). Sequences were submitted for analysis of
DRMs to the Stanford Database [14]. To check for trans-
mission of DRMs, phylogenetic trees were reconstructed
using the LANL subtype C ancestral sequence as outgroup
under the GTR + gamma model of DNA substitution
implemented RAxML7.0.3 [15] with all parameters opti-
mised by RAxML. Confidence levels in the groupings in
the phylogeny were assessed using 1000 bootstrap repli-
cates as part of the RAxML phylogeny reconstruction.
Permission for the study was received from the National
Health Sciences Research Committee, Malawi, and the
Ethics Committee of the London School of Hygiene and
Tropical Medicine, UK
Results
One hundred and forty nine subtype C sequences were
generated from 75 individuals, 65 of which were from
blood samples collected at baseline (and reported to be
ART naïve). DRMs were found in sequences from 15
individuals (20%) overall, and for 10 individuals (15.4%)
the mutations were found in sequences from baseline
samples (drug naïve). Details of observed drug resistance
mutations are summarized in Table 1. Seven individuals
showed DRMs (or ambiguities that suggest the presence
of DRMs) to NRTIs used in Karonga with 6/7 showing
the mutation V118I. While ten individuals showed the
presence of DRMs to NNRTIs only five showed DRMs
against therapies used in Karonga, the most common
being Y181C and G190AE.
Some individuals showed a discrepancy in the pre-
sence and type of DRMs over time. Three patients (Pt2,
Pt12 and Pt66) did not show any DRMs at baseline but
showed DRMs at subsequent time points (Table 1).
Patient 2 also showed a significant drug resistance-
related ambiguity (K103KN) in the consensus sequence
at 6 months while a different DRM was seen at 9
months (Y181C). No DRM was seen in the sequence
from the 12-month sample. Patient 12 showed a similar
pattern, where an NNRTI associated mutation
(Y181NY) was present in the sequence collected at 3
months, while the sequences at baseline and 12 months
did not show any DRMs (Table 1). Both individuals
(patient 2 and patient 12) showed immune failure (their
CD4 count did not rise over 200 cells/mm3 after 12
months on ART).
Three patients (Pt32, Pt61 and Pt76) showed DRMs at
baseline but different DRMs at later time-points (Table 1)
with patient 32 showing a high variation of DRMs across
timepoints. The baseline sequence from patient 61 showed
V118I and K219R, the latter of which was not found in the
sequence at 9 months. In Patient 76, the baseline sequence
showed the ambiguity Y181CY, with two additional
NNRTI mutations (V90IV and H221HY), the 6 months
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sequence showed the full DRM at position 181 while
sequences retrieved from 3 month and 9 month samples
showed no DRMs (Table 1).
There was no evidence of transmission of drug resistant
HIV between the individuals examined here. Sequences
retrieved from each individual grouped monophyletically
in all cases. Few individuals showed their sequences clus-
tering with other patients with high bootstrap support but
DRMs were not present in both individuals, e.g. sequences
from patient 47 and 77 formed a cluster together and are
from the same geographical area but while patient 77
showed DRMs, patient 47 did not (data not shown).
Table 1 Mutations associated with antiretroviral drug resistance found in sequences from HIV-1 subtype C infected
individuals from Karonga District Malawi
Patient Comments Sex Time point (month) NRTI NNRTI
Patient 2 * Immune Failure F 0 No DRMs No DRMs
6 No DRMs K103KN
9 No DRMs Y181C
12 No DRMs No DRMs
Patient 5 F 0 No DRMs E138A
6 No DRMs E138A
Patient 12 * Immune Failure F 0 No DRMs No DRMs
3 No DRMs Y181NY
12 No DRMs E138A
Patient 14 M 12 No DRMs E138A
Patient 20 Immune Failure F 0 No DRMs E138A
3 No DRMs E138A
6 No DRMs E138A
9 No DRMs E138A
Patient 32 * M 0 No DRMs V90I
6 M41MR, T215ST No DRMs
12 No DRMs No DRMs
15 No DRMs V108AV
22 No DRMs No DRMs
Patient 42 * M 0 No DRMs No DRMs
0 V118IV No DRMs
3 V118I No DRMs
Patient 45 F 0 No DRMs V106I, E138A, G190A
6 No DRMs V106I, E138A, G190A
Patient 61 * F 0 V118I, K219R No DRMs
9 V118I No DRMs
Patient 66 M 0 No DRMs No DRMs
9 V118IV No DRMs
Patient 76 * M 0 No DRMs V90IV, Y181CY, H221HY
3 No DRMs No DRMs
6 No DRMs Y181C
9 No DRMs No DRMs
Patient 77 F 0 V118I No DRMs
12 V118I No DRMs
Patient 91 0 V118I No DRMs
Patient 93 M 6 V118I E138A
12 V118I E138A
Patient 95 0 No DRMs E138A
Mutations in bold are against current ART drugs in use in Karonga District.
* Patients showing discrepancies in DRMs between different timepoints
Bansode et al. AIDS Research and Therapy 2011, 8:38
http://www.aidsrestherapy.com/content/8/1/38
Page 3 of 5
Discussion
Through genotyping RT from HIV-1 subtype C infected
individuals on ART using a consensus sequencing
approach, we have shown the presence of mutations asso-
ciated with drug resistance to the therapy used in Karonga
District. Drug resistance to Trioimmune® occurred at an
overall rate of 20% of individuals (both drug naïve and
drug exposed, which is comparable to rates found in other
African countries [4-7,16-18] but, as expected, greater
than that described in our previous study (7.5%) [8] which
did not include individuals currently on therapy.
Patients 2 and 12, both females, had immune failure
prior to ART initiation and continued to exhibit immune
failure while on ART (i.e. their CD4 counts did not rise
above 200 cells/mm3 after 12 months on therapy). While
neither showed DRMs from baseline samples they subse-
quently showed the DRMs Y181C and Y181NY respec-
tively, which is responsible for high-level resistance to
NVP, the NNRTI used in 1st line therapy in Karonga.
Patient 2 also showed a DRM (K103KN), after 6th months
of ART, which also causes high-level resistance to NVP.
For these, and a third individual who also exhibited
immune failure, it will be important to monitor the indivi-
duals and DRMs at subsequent timepoints in case of con-
tinued immune failure and development of clinical failure.
Three drug-naïve individuals (Pt 61, Pt 77, Pt 91)
showed V118I while another (Pt 42) showed an ambiguity
at this position (V118IV). According to the Stanford HIV
drug resistance database, V118I is responsible for low-
level resistance to 3TC and possibly to other NRTIs when
present with other mutations. The mutation has been
reported to occur in ~2% of untreated persons infected
with subtype C and with increased frequency in persons
receiving multiple NRTIs [19] and so it may not be unex-
pected to find it in this cohort. It was the only DRM found
in all three previous studies of drug resistance in Malawi
[9,13,20] and was also reported in subtype C infected drug
naïve patients from Zambia [21], Zimbabwe [22] and
South Africa [19]. It has been suggested that along with
drug resistance, the V118I mutation alone is a marker of
advanced HIV infection and disease progression [23]. As
no associated mutations were found in the three indivi-
duals, and they all had a satisfactory response to treat-
ment, this mutation is probably not significant but may
become important if a second mutation were to arise.
Mutation G190A (shown in a female patient 45) accord-
ing to the Stanford drug resistance database, causes high-
level resistance to NVP and intermediate resistance to
EFV. The mutation was present at baseline in this indivi-
dual and could indicate acquisition of drug resistant HIV.
However, although all individuals participating in the ART
cohort study were reported to be ART naïve, we cannot
exclude the possibility that some individuals had received
some form of ART previously, (e.g. received prevention of
mother to child transmission treatment) and did not dis-
close this fact. The DRM does not appear to have had any
major effect on treatment to date, as this individual also
has had a satisfactory response.
Drug resistance mutations were found to emerge in
some individuals during ART. Patient 32 showed a
number of NNRTI mutations and a number of ambigu-
ities at sites important in susceptibility to NRTIs (e.g.
the mutation T215S is one of many transitions between
wild type and the mutations Y and F [24]). Most of the
ambiguities do not reduce NRTI susceptibility but their
presence may suggest that the DRM may also be present
[25]. This patient had made additional visits to the clinic
outside of the routine ART cohort study because of dia-
betic complications. Additional sequences produced
from samples taken at those additional visits showed
further mutations associated with drug resistance to
NVP and AZT (M41L, M184I, G190E- data not shown),
however he has had a satisfactory response to treatment
to date.
This study was based on a consensus sequencing
approach from provirus due to the difficulty of amplify-
ing HIV from RNA from individuals on ART. While
provirus may not provide as clear a picture of the geno-
type of the circulating virus as would be retrieved from
RNA in individuals who have been infected for long per-
iods of time, it has been shown in patients with virologi-
cal failure that archived resistance mutations previously
detected in the proviral DNA were observed in the
sequences obtained from the plasma viruses at the time
of virological failure [26]. When the selective pressure
provided by ART compromises the current plasma
population, archived viruses can re-emerge [27]. There-
fore documenting the proviral population is also impor-
tant in monitoring the emergence of drug resistance.
Despite the presence of DRMs to current therapy in
some individuals, and immune failure in three, no signs
of clinical failure were seen during this study. This
cohort will continue to be monitored as part of the Kar-
onga Prevention Study so that the long-term impact of
these mutations can be assessed.
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